Fed. Circ. Rejects Narcan Maker's Redo Bid In Patent Suit
The Federal Circuit said it won't review a split appellate panel's decision that stood by a New Jersey judge's invalidation of claims in four patents covering Adapt Pharma's opioid overdose medication...To view the full article, register now.
Already a subscriber? Click here to view full article